» Articles » PMID: 11252649

The High Affinity Inositol Transport System--implications for the Pathophysiology and Treatment of Bipolar Disorder

Overview
Journal Bipolar Disord
Specialty Psychiatry
Date 2001 Mar 17
PMID 11252649
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The 'inositol-depletion hypothesis' postulates that the therapeutic effects of lithium are due to inhibition of inositol monophosphatase, which leads to depletion of brain cells of myo-inositol and consequently to dampening of phosphoinositide (PI) signaling. This article examines the potential relevance of an alternative mechanism for inositol depletion: inhibition of myo-inositol uptake that proceeds via the sodium/myo-inositol cotransport (SMIT). We discuss recent in vitro experiments that show a pronounced downregulation of SMIT after chronic treatment with lithium, carbamazepine, and valproate at therapeutically relevant concentrations. It is concluded that downregulation of SMIT could represent a common mechanism of action of mood stabilizers.

Citing Articles

Inference of differentially expressed genes using generalized linear mixed models in a pairwise fashion.

Machado D, Brustolini O, Martins Y, Grivet Mattoso Maia M, de Vasconcelos A PeerJ. 2023; 11:e15145.

PMID: 37033732 PMC: 10078460. DOI: 10.7717/peerj.15145.


Lithium as a Neuroprotective Agent for Bipolar Disorder: An Overview.

Ochoa E Cell Mol Neurobiol. 2021; 42(1):85-97.

PMID: 34357564 PMC: 11441275. DOI: 10.1007/s10571-021-01129-9.


IP3 accumulation and/or inositol depletion: two downstream lithium's effects that may mediate its behavioral and cellular changes.

Sade Y, Toker L, Kara N, Einat H, Rapoport S, Moechars D Transl Psychiatry. 2016; 6(12):e968.

PMID: 27922641 PMC: 5315558. DOI: 10.1038/tp.2016.217.


Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics.

Alda M Mol Psychiatry. 2015; 20(6):661-70.

PMID: 25687772 PMC: 5125816. DOI: 10.1038/mp.2015.4.


Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.

Niciu M, Ionescu D, Mathews D, Richards E, Zarate Jr C CNS Spectr. 2013; 18(5):242-51.

PMID: 23472710 PMC: 3936782. DOI: 10.1017/S1092852913000138.